TRK 950Alternative Names: TRK-950
Latest Information Update: 16 Dec 2016
At a glance
- Originator Toray
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Solid tumours
Most Recent Events
- 08 Dec 2016 Toray Industries plans a first-in-human phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA and France (IV) (NCT02990481)
- 29 Nov 2016 Investigation in Solid tumours in USA (IV) before November 2016